Spica Therapeutics SA
0.7 FTESpica Therapeutics reported total assets of €7.45m at the end of the 2025 financial year (annual accounts filed with the NBB on 21 May 2026), with 0.7 full-time equivalent.
By total assets for 2025, Spica Therapeutics ranks among the 200 largest of the 993 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year. Largest companies in the sector →
The score of Spica Therapeutics shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Spica Therapeutics's annual accounts
| 2025 | |
|---|---|
| Net result | −€2.73m |
| Equity | €6.16m |
| Cash | 996,528 € |
| EBITDA | −€1.04m |
| Total assets | €7.45m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 21 May 2026
Spica Therapeutics's financial analysis
- Solvency82.6%sector median: 61.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Spica Therapeutics
Spica Therapeutics's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1012.800.853
- VAT number
- BE1012800853
- Peppol
- Registered · 0208:1012800853 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 26 Aug 2024
- Registered office
- 2600 Antwerp
- Size
- Micro · 0.7 FTE
- Latest accounts
- 2025 · filed on 21 May 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Spica Therapeutics (SA) has been based in Antwerp since 2024, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of €2.73m and equity of €6.16m; its revenue is not published. With 0.7 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 82.6%, above the median of its sector (61.7%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Spica Therapeutics
Companies in the same business, of comparable size and area, outside its group.
- EXO Biologics Research and experimental development on natural sciences and engineering Liège · balance sheet €11.7m
- XpressBioX Manufacture of basic pharmaceutical products Herstal · balance sheet €8.92m
- Boehringer Ingelheim Veterinary Medicine Belgium NV Research and experimental development on natural sciences and engineering Evergem · balance sheet €6.51m
- Temmune Therapeutics Manufacture of pharmaceutical preparations Mechelen · balance sheet €3.43m
- GRNR Invest Manufacture of basic pharmaceutical products Zemst · balance sheet €2.26m
- Grand Medical (Europe) Research and experimental development on natural sciences and engineering Niel · balance sheet 135,260 €
- Asterion Research & Development Research and experimental development on natural sciences and engineering Ghent · balance sheet €2.31m
- Minoryx Therapeutics BE Research and experimental development on natural sciences and engineering Charleroi · balance sheet €3.87m
Frequently asked questions about Spica Therapeutics
What is the revenue of Spica Therapeutics?
Spica Therapeutics files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Spica Therapeutics?
In Belgium, the VAT number is the company number prefixed with BE: BE1012800853 for Spica Therapeutics, if the company is VAT-registered. Its company number (CBE) is 1012.800.853.
Where is the registered office of Spica Therapeutics?
According to the CBE register, the registered office of Spica Therapeutics is in 2600 Antwerp.
What is the equity of Spica Therapeutics?
At the close of the 2025 financial year, the equity of Spica Therapeutics amounts to 6,155,327 €, a solvency of 82.6% of total assets.
How many people work at Spica Therapeutics?
0.7 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Spica Therapeutics?
The register lists 12 active mandates at Spica Therapeutics. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
How large is Spica Therapeutics within its sector?
By total assets for 2025, Spica Therapeutics ranks among the 200 largest of the 993 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year.
The full file of Spica Therapeutics
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →